CEFIZOX DIN 01919504
Health Canada record
| Active ingredient(s) | CEFTIZOXIME SODIUM 2 G |
|---|---|
| Dosage form | Powder For Solution |
| Route | Intramuscular; Intravenous |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | J01DD07 CEFTIZOXIME |
| Original market date | 31-Dec-1988 |
| Current status date | 19-Oct-2005 |
| Source | Health Canada DPD |
Establishment licence of the holder
GlaxoSmithKline Inc. — licence 100630, currently licensed, last inspection rating C (2025-09-15).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing CEFTIZOXIME SODIUM
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 01919490 | CEFIZOX | GLAXOSMITHKLINE INC | Powder For Solution | CEFTIZOXIME SODIUM 1 G | Cancelled Post Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 2116 | 2001-08-15 | New Drug Submission (NDS) | CHANGE IN MANUFACTURER NAME |
International API supply for CEFTIZOXIME SODIUM
0 valid EDQM Certificates of Suitability from 0 holders. 1 active FDA Drug Master Files.
Request a quote for CEFIZOX